Demyelination of nerve fibers and progressive neurological deterioration are hallmarks of Multiple Sclerosis (MS), a chronic, inflammatory, and neurodegenerative disease of the central nervous system (CNS). Since B-cells are thought to play a major part in the pathophysiology of MS, treatments that specifically target these cells have been developed. Bruton's Tyrosine Kinase (BTK) inhibitors have become a viable treatment choice among them. This article examines the clinical effectiveness, mechanism of action, and future prospects of BTK inhibitors in the management of multiple sclerosis.

1. Montalban, X., Comi, G., et al. (2019). Efficacy and Safety of Evobrutinib in Patients with Relapsing Multiple Sclerosis: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Trial. Lancet Neurology, 18(2), 127-135. DOI: 10.1016/S1474-4422(18)30499-9

2. Bar-Or, A., Wiendl, H., et al. (2021). Tolebrutinib in Patients with Relapsing Multiple Sclerosis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial. Journal of the American Medical Association Neurology, 78(7), 927-936. DOI: 10.1001/jamaneurol.2021.1427

3. Gommerman, J. L., & Weiner, H. L. (2015). Modulation of Autoimmune Neuropathies by B Cells: The Balance Between Protective and Pathogenic Functions. Journal of Clinical Investigation, 125(4), 1320-1328. DOI: 10.1172/JCI78092

4. Gordon, R. A., & Mankoff, A. D. (2020). Understanding the Role of Bruton’s Tyrosine Kinase in Multiple Sclerosis: A Review of Current Data and Future Directions. Multiple Sclerosis Journal, 26(11), 1392-1402. DOI: 10.1177/1352458519897890

5. Reinhardt, M., & Konig, M. (2022). Bruton’s Tyrosine Kinase Inhibition as a Therapeutic Strategy in Multiple Sclerosis: Preclinical Rationale and Clinical Evidence. Journal of Neuroinflammation, 19(1), 46-57. DOI: 10.1186/s12974-022-02403-y